These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 25345538)

  • 21. Methods for Experimental Allergen Immunotherapy: Subcutaneous and Sublingual Desensitization in Mouse Models of Allergic Asthma.
    Hesse L; Petersen AH; Nawijn MC
    Methods Mol Biol; 2021; 2223():295-335. PubMed ID: 33226602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma.
    Agache I; Lau S; Akdis CA; Smolinska S; Bonini M; Cavkaytar O; Flood B; Gajdanowicz P; Izuhara K; Kalayci O; Mosges R; Palomares O; Papadopoulos NG; Sokolowska M; Angier E; Fernandez-Rivas M; Pajno G; Pfaar O; Roberts GC; Ryan D; Sturm GJ; van Ree R; Varga EM; van Wijk RG; Yepes-Nuñez JJ; Jutel M
    Allergy; 2019 May; 74(5):855-873. PubMed ID: 31095767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial.
    Karakoc-Aydiner E; Eifan AO; Baris S; Gunay E; Akturk E; Akkoc T; Bahceciler NN; Barlan IB
    J Investig Allergol Clin Immunol; 2015; 25(5):334-42. PubMed ID: 26727762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An observational, real-life safety study of a 5-grass pollen sublingual tablet in children and adolescents.
    Eberle P; Brueck H; Gall R; Hadler M; Sieber J; Karagiannis E
    Pediatr Allergy Immunol; 2014 Dec; 25(8):760-6. PubMed ID: 25378225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma.
    Hesse L; Nawijn MC
    Methods Mol Biol; 2017; 1559():137-168. PubMed ID: 28063043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
    Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
    Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of Sublingual Immunotherapy in the Treatment of HDM-Induced Nasobronchial Allergies: A 3-Year Randomized Case-Control Study From Kashmir.
    Baba SM; Rasool R; Gull A; Qureshi TA; Beigh AH; Qadri Q; Shah ZA
    Front Immunol; 2021; 12():723814. PubMed ID: 34721385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Requirements for acquiring a high-quality house dust mite extract for allergen immunotherapy.
    Frati F; Incorvaia C; David M; Scurati S; Seta S; Padua G; Cattaneo E; Cavaliere C; Di Rienzo A; Dell'Albani I; Puccinelli P
    Drug Des Devel Ther; 2012; 6():117-23. PubMed ID: 22654506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New administration routes for immunotherapy].
    Martorell Aragonés A
    Allergol Immunopathol (Madr); 2000; 28(3):93-102. PubMed ID: 10867377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy for house-dust mite allergy.
    Nelson HS
    Allergy Asthma Proc; 2018 Jul; 39(4):264-272. PubMed ID: 30095391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes.
    Keles S; Karakoc-Aydiner E; Ozen A; Izgi AG; Tevetoglu A; Akkoc T; Bahceciler NN; Barlan I
    J Allergy Clin Immunol; 2011 Oct; 128(4):808-815.e7. PubMed ID: 21641635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells.
    O'Hehir RE; Gardner LM; de Leon MP; Hales BJ; Biondo M; Douglass JA; Rolland JM; Sandrini A
    Am J Respir Crit Care Med; 2009 Nov; 180(10):936-47. PubMed ID: 19696440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.
    Eifan AO; Akkoc T; Yildiz A; Keles S; Ozdemir C; Bahceciler NN; Barlan IB
    Clin Exp Allergy; 2010 Jun; 40(6):922-32. PubMed ID: 20100188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Developmental history of sublingual immunotherapy].
    Du W; Maekawa Y; Natsui K
    Nihon Yakurigaku Zasshi; 2019; 154(1):6-11. PubMed ID: 31308350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sublingual immunotherapy not effective in house dust mite-allergic children in primary care.
    de Bot CM; Moed H; Berger MY; Röder E; Hop WC; de Groot H; de Jongste JC; van Wijk RG; Bindels PJ; van der Wouden JC
    Pediatr Allergy Immunol; 2012 Mar; 23(2):150-8. PubMed ID: 22017365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New perspectives in allergen specific immunotherapy driven by big trials with house dust mite sublingual SQ
    Vitiello G; Maltagliati L; Rossi O
    Clin Mol Allergy; 2020; 18():10. PubMed ID: 32536827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamic and pharmacokinetic evaluation of house dust mite sublingually administered immunotherapy tablet in the treatment of asthma.
    Mauro M; Boni E; Makri E; Incorvaia C
    Expert Opin Drug Metab Toxicol; 2015; 11(12):1937-43. PubMed ID: 26565665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma.
    Ozdemir C; Yazi D; Gocmen I; Yesil O; Aydogan M; Semic-Jusufagic A; Bahceciler NN; Barlan IB
    Pediatr Allergy Immunol; 2007 Sep; 18(6):508-15. PubMed ID: 17680909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the long-term efficacy of subcutaneous and sublingual immunotherapies in perennial rhinitis.
    Tahamiler R; Saritzali G; Canakcioglu S; Ozcora E; Dirican A
    ORL J Otorhinolaryngol Relat Spec; 2008; 70(3):144-50. PubMed ID: 18391573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis.
    Demoly P; Kleine-Tebbe J; Rehm D
    Allergy; 2017 Oct; 72(10):1576-1578. PubMed ID: 28273339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.